Full-Time

Sr. Scientist

Peptide / Bio-organic Chemistry

Updated on 4/16/2025

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Compensation Overview

$108.6k - $157.3k/yr

+ Bonus + Equity Incentive Program

Senior

Company Does Not Provide H1B Sponsorship

San Diego, CA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • BS/BA degree in chemistry or closely related field and 5+ years of experience OR
  • MS/MA degree in chemistry or closely related field and 3+ years of similar experience OR
  • PhD in chemistry or related field and 2+ years of similar experience
  • Proficient in all aspects of modern peptide synthesis, purification and analysis; capable of immediate independent laboratory work on solid- and solution-phase chemistry
  • Strong publication record of accomplishment
  • Strong understanding of peptide structure and associated biophysical techniques to assess peptide structure, stability and behavior in solution
  • Experience in protein-peptide bioconjugation and purification a plus
  • Excellent interpersonal skills with strong oral and written communication abilities
  • Assimilates data and research findings outside of Neurocrine for application to new scientific projects
  • Advanced knowledge and demonstrated ability working with / recommending a variety of laboratory equipment/tools
  • Excellent computer, communications, problem-solving, and analytical thinking skills
  • Ability to meet multiple deadlines across a variety of projects/programs, with a high degree of accuracy and efficiency
Responsibilities
  • Lead projects and teams towards agreed upon goals, ultimately working towards clinical candidate peptide nomination
  • Synthesis, purification and characterization of peptides, small proteins and chemically-modified analogs using state-of-the-art synthesis, purification, analytical and biophysical techniques
  • Contributes to project teams towards agreed upon goals, ultimately working towards candidate peptide nomination
  • Independent data-driven optimization of peptide SAR
  • Effective communication of scientific rationale, results and interpretation at project, team and departmental meetings
  • Active collaboration and sharing of expertise with colleagues
Desired Qualifications
  • Experience in protein-peptide bioconjugation and purification a plus
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of a new tardive dyskinesia treatment strengthens Neurocrine's market leadership.
  • Investment in AI-driven drug discovery accelerates identification of neuropsychiatric therapeutic targets.
  • Collaboration with Voyager Therapeutics shows promise in gene therapies for neurological diseases.

What critics are saying

  • Increased competition from Biogen and Sage Therapeutics may impact market share.
  • Potential delays in osavampator development could affect market entry timeline.
  • Financial pressure from Takeda collaboration amendment may strain resources.

What makes Neurocrine Biosciences unique

  • Neurocrine focuses on under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.
  • The company has a strong pipeline in rare diseases, enhancing its market position.
  • Neurocrine's strategic collaborations, like with Takeda, expand its drug development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

Contract Pharma
Apr 4th, 2025
Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer

Neurocrine Biosciences Inc. has appointed Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025.

BioSpace
Mar 12th, 2025
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

SAN DIEGO, March 11, 2025 /PRNewswire/ - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025.

PR Newswire
Mar 11th, 2025
Neurocrine Biosciences To Present At The Stifel 2025 Virtual Cns Forum

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer Eiry Roberts will present at the conference.The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.About Neurocrine BiosciencesNeurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders

PR Newswire
Feb 21st, 2025
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.William Rastetter, Chairman of the Board of Directors of Neurocrine Biosciences, said, "This authorization reflects our approach to capital allocation that balances driving sustained revenue growth through investing in our commercial products, INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders."Under the new authorization, repurchases may be made from time to time at management's discretion through a variety of methods, such as open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws.About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life- changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders. The company's diverse portfolio includes U.S

PR Newswire
Jan 27th, 2025
Neurocrine Biosciences Announces Amendment To Strategic Collaboration With Takeda To Develop And Commercialize Osavampator (Formerly Nbi-1065845/Tak-653)

- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator- Takeda Reacquires Rights to Osavampator in JapanSAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments."This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible," said Kyle Gano, Ph.D., Chief Executive Officer at Neurocrine Biosciences. "With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year.""With its long-standing expertise developing therapies for serious psychiatric disorders, Neurocrine is the ideal partner to develop osavampator," said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda